Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Drug Resistance is Scopus-indexed (Q1, CiteScore 10.3), WoS ESCI. Published by OAE Publishing Inc..
Checked against the index lists dated .
ISSN 2578-532XVerify ISSN ↗
Publisher: OAE Publishing Inc.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 20 / 278 | 92nd | Q1 |
| Cancer Research | 46 / 233 | 80th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2018–2025, best quartile Q1, CiteScore 10.3.
Cancer Drug Resistance is Q1 in Pharmacology (medical) (rank 20 of 278) and Q1 in Cancer Research (rank 46 of 233), by CiteScore 2025.
Cancer Drug Resistance is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 10.3, which places it in quartile Q1 at the 92nd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.775, quartile Q1, with an H-index of 36.
Cancer Drug Resistance is published by OAE Publishing Inc. Its ISSN is 2578-532X.
Yes — indexed in the Emerging Sources Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cancer Drug Resistance has an h-index of 39 and a 2-year mean of 5.79 citations per paper (OpenAlex). Its Scopus CiteScore is 10.3, quartile Q1. On 2-year citations it ranks #19 of 271 Scopus journals in Pharmacology (medical).
Cancer Drug Resistance published 63 papers in 2025; its busiest recent year was 2019 with 87. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from China (52.3%), United States (14.6%) and Italy (7.9%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.